Medicare 2024 Diabetes Prescribing Aid
	Date: 
	
		05/28/24 
	
	
	2024 Diabetes Prescribing Aid MAPD: D-SNP, C-SNP, & PPO
Benefits subject to evidence of coverage. Information on copays/cost sharing, deductibles, and gap coverage can be found in the Summary of Benefits on our website:
H0351, H5590: Wellcare By Allwell                  H8553: Wellcare
| 2024 Preferred Insulin Products  |   | 
| Fast Acting | - Fiasp (insulin aspart)
 - Novolog
  
 | 
| Short Acting | -  Novolin R (Note: Brand RELION is not covered).
  
 | 
| Intermediate Acting | - Novolin N (Note: Brand RELION is not covered)
  
 | 
| Long Actiing | - Basaglar (insulin glargine).
 - Tresiba (insulin degludec)
 - Toujeo (insulin glargine).
 - Toujeo Max (insulin glargine)
  
 | 
| Combinations | Insulins 
- Novolog Mix 70/30.
 - Novolin 70/30
  
Insulin + GLP-1 receptor agonist 
- Soliqua (insulin glargine + lixisenatide), Xultophy (insulin degludec+ liraglutide)
  
 | 
-  C-SNP plans (Wellcare Specialty No Premium HMO C-SNP): Tier 6, $0 or low copay 
 - D -SNP plans (Wellcare Dual Liberty HMO D-SNP): Tier 1, $0 or low copay.
 - All other plans: Tier 3 with maximum copay of $35 per month based on Inflation Reduction Act
  
 |   | 
For more than 20 years, Wellcare has ofered a range of Medicare products, which ofer afordable coverage beyond OriginalMedicare. Beginning Jan. 1, 2022, our afliated Medicare brands, including Allwell, transitioned to a newly refreshed and unifid Wellcare brand. If you have any questions, please contact Provider Relations.
| 2024 Preferred Anti-Diabetic (non-insulin) Medications | 
GENERIC ORAL ANTI-DIABETIC MEDICATIONS: 
- Biguanide: metformin, metformin ER (generic for Glucophage XR only).
 - Thiazolidinedione: pioglitazone.•  Alpha-Glucosidase inhibitor: acarbose.
 - Meglitinide analogue: nateglinide, repaglinide.
 - Combinations: glipizide/metformin, pioglitazone/metformin, pioglitazone/glimepiride.
  
 | 
- C-SNP plans (Wellcare Specialty No Premium HMO C-SNP): Tier 1, $0 or low copay. 
 - D-SNP plans (Wellcare Dual Liberty HMO D-SNP): Tier 1, $0 or low copay. 
 - All other plans: Tier 6, $0 or low copay.
  
 | 
 
DPP-4 INHIBITOR:     
DPP-4 COMBINATIONS: 
- Glyxambi, Janumet, Janumet XR,Jentodueto, Jentodueto XR, Trijardy.
  
 | 
- C-SNP plans (Wellcare Specialty No Premium HMO C-SNP): Tier 6, $0 or low copay, EXCEPT Glyxambi and Trijardy, which are Tier 3. 
 - D-SNP plans (Wellcare Dual Liberty HMO D-SNP): Tier 1, $0 or low copay. 
 - All other plans: Tier 3.
  
 | 
 
SGLT-2 INHIBITOR: 
- Farxiga, Jardiance, Invokana.
  
SGLT-2 INHIBITOR COMBINATION: 
- Glyxambi, Synjardy, Synjardy XR, Trijardy,Xigduo, Invokamet*, Invokamet XR.*
  
 | 
-  *Invokana, Invokamet, and Invokamet XR: NONFORMULARY for D-SNP plans (Wellcare DualLiberty HMO D-SNP) and Tier 4 for all other plans.
 - Farxiga,  Jardiance – Tier 1, $0 or low copay, for D-SNP plans (Wellcare Dual Liberty HMO D-SNP),and Tier 3 for all other plans.
  
 | 
GLP-1 AGONIST: 
- Bydureon, Ozempic, Mounjaro, Rybelsus, Trulicity.
  
 | 
- D -SNP plans (Wellcare Dual Liberty HMO D-SNP): Tier 1, $0 or low copay.  
 - All other plans: Tier 3. 
 - All plans require prior authorization.
  
 | 
 
2024 Preferred Blood Glucose Meters and Strips 
One Touch Verio Reflect or Verio Flex meter and One Touch Verio test strips; One Touch Ultra 2meter and One Touch Ultra test strips 
 | 
Test Strip Quantity Limits: 
- Non-insulin users: 100 strips/90 days
 - Insulin  users: 100 strips/25 days
  
 | 
| Note: Continuous Glucose Monitoring (CGM) systems require Prior Authorization(PA). FreeStyle Libre or DexCom are preferred/PA required. PA criteria: DM diagnosis, insulin-treated, has had more than one level 2 hypoglycemic event (BG < 54 mg/dL) that persists despite more than one attempt toadjust medications and/or modify diabetes treatment plan OR one level 3 hypoglycemic event (BG< 54 mg/dL) characterized by altered mental and/or physical state requiring third-party assistancefor treatment, seen by provider in last six months, and will have follow-up appointments every sixmonths to document adherence to both the CGM regimen and diabetes treatment plan. The CoverageDetermination form for PA request is available on our website. |